In patients with high genetic risk for #AMD progression, healthy lifestyle behaviors could still lower risk of advanced AMD. 55-60% of development of advanced AMD is due to these lifestyle factors. Presented by Joanna Seddon at #RSLisbon2024 @RetinaSociety

Use of levodopa was associated with 32% reduced development of new-onset geographic atrophy. It may dilate choroidal vasculature or reduce oxidative stress. However difficult to determine effect of Parkinson’s. Presented by Jeremy Lavine at #RSLisbon2024 @RetinaSociety

Metformin use shown to be associated with lower risk of new #AMD and dry AMD. Presentation at #RSLisbon2024 by Dmitra Skondra shows association between metformin use and 47% reduced odds of geographic atrophy in patients without diabetes @RetinaSociety

Faricimab associated with greater reductions in pigment epithelial detachment. Better early drying of fluid associated with greater likelihood of extension to 16 weeks. Over 50% could have been extended to 20 weeks. Terrific talks at #RSLisbon2023 @RetinaSociety @TheIVIpodcast

Phase 2 subretinal gene therapy of ABBV-RGX-314 in previously treated wet AMD showed good tolerance with few cases of inflammation responsive to steroid drops + stable vision and edema with over 70% injection free over 6 mos. @allenho #RSLisbon2024 @RetinaSociety @Wills_Eye

Study of real world use of Eylea HD by >300 retina docs showed mean extension of 14 days by the 4th EHD injection compared to interval prior to being switched. Low rates of adverse events. Presented by @NJRetinaDoc at #RSLisbon2024 @RetinaSociety @MidAtl_Retina @Wills_Eye

Fascinating study on use of intravitreal methotrexate and rituximab for treatment of bilateral diffuse uveal melanocytic proliferation presented by Jasmine Francis at #RSLisbon2024, showing potential for long term vision improvement and preservation. @RetinaSociety

Genome wide association study found central serous retinopathy was associated with vascular endothelial protein tyrosine phosphatase which is modulated by faricimab. @LizzyRossin presented a small case series showing fluid resolution with faricimab injections #RSLisbon2024

Smaller ellipsoid zone lesion size, younger age, and lack of foveal involvement portended a greater reduction in disease progression with NT-501 (encapsulated cell technology) for macular telangiectasis type 2. Presented by Anthony Capone at #RSLisbon2024 @RetinaSociety

Very interesting study by @GlennYiuMD at #RSLisbon2024 about modifying rod photoreceptors to be more cone-like in order to mitigate retinal pigment epithelial atrophy in a geographic atrophy animal model. @RetinaSociety

Phase 2 trial of bel-sar for choroidal melanoma showed 80% local tumor control rate with 90% having vision preservation and a very good safety profile presented by Ivana Kim at #RSLisbon2024 @RetinaSociety

Outstanding talk by @eyeamprithvi at #RSLisbon2024 on his study of using aqueous humor to determine metastatic risk potential of uveal melanoma @RetinaSociety

Fantastic diabetic retinopathy session at #RSLisbon2024 with three great talks focusing on health disparities and inequities in diabetic retinopathy by @DrKNwan, Brian VanderBeek, and Anjali Shah @RetinaSociety

Concept of suprachoroidal injection of viscoelastic in rhegmatgenous retina detachment to create a temporary buckle without need for gas or positioning. Terrific presentation of 6 cases by Rajeev Muni at #RSLisbon2024 @RetinaSociety

New #OphthalmologyJournal #Podcast! @iDrFeng interviews @momenaeib & @JasonHsuMD on the incidence, timing, risk factors, and outcomes of recurrent retinal detachment after phacoemulsification https://t.co/PS2zi2nI2q

Thanks @SArepalliMD @RetinalPhys for highlighting our study which found that cumulative endophthalmitis risk seems to decrease with greater number of intravitreal injections. Check out the article for some of our hypotheses

Enjoyed this opportunity to better understand how #MacularDegeneration impacts our patients and how what we do as retina specialists can help improve quality of life

The risk of post-injection endophthalmitis doesn’t increase linearly as patients receive more injections but is higher early on and lower later in the course of treatment. Check out our theories: https://t.co/o4pf9iNUKG @RIsrailevichMD @HanaMansourMD @YoshiYonekawaMD @Wills_Eye

📣Attention Retina docs, your input is needed! @asrsdocs has proposed a Focused Practice Designation in Medical/Surgical Retina to the ABO.🚀 First time a subspecialty could receive such designation in #ophthalmology. Public comment open til 1/26/24. https://t.co/p4rwPFX8Ng 🌐👁️